Rickets: New insights into a re-emerging problem

Current Opinion in Orthopaedics

Volumn 18, Issue 5, 2007, Pages 486-493

  Dimitri, Paul ^a   Bishop, Nick ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

1,25 hydroxyvitamin D; 25 hydroxyvitamin D; Hypophosphataemic rickets; Rickets; Vitamin D; Vitamin D dependent rickets

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 1,25 HYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCITRIOL; CALCIUM; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; GLUCONATE CALCIUM; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

CALCIUM DEFICIENCY; CHILD HEALTH; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG HALF LIFE; DRUG MEGADOSE; GENE MUTATION; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MUTATOR GENE; NEWBORN DISEASE; OSTEOMALACIA; PATHOGENESIS; PHEX GENE; PHOSPHATE DEFICIENCY; PHYSIOTHERAPY; PREGNANT WOMAN; PREMATURITY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; RICKETS; SEIZURE; SINGLE DRUG DOSE; SUN EXPOSURE; VITAMIN D DEFICIENCY; VITAMIN D DEPENDENT RICKETS TYPE 1; VITAMIN D DEPENDENT RICKETS TYPE 2; VITAMIN D METABOLISM;

EID: 34547914799     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/BCO.0b013e3282b97118     Document Type: Review

References (108)

1. Dawson-Hughes B. Racial/ethnic considerations in making recommendations for vitamin D for adult and elderly men and women. Am J Clin Nutr 2004; 80:1763S-1766S.
2. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135:317-322.
3. Gartner LM, Greer FR. Prevention of rickets and vitamin D deficiency: new guidelines for vitamin D intake. Pediatrics 2003; 111:908-910.
4. Bodnar LM, Simhan HN, Powers RW, et al. High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. J Nutr 2007; 137:447-452. This study highlights and identifies the level of vitamin D insufficiency and deficiency in pregnant mothers and neonates in the US. The authors propose a need to increase prenatal vitamin D supplementation.
5. Lee JM, Smith JR, Holick MF, et al. Vitamin D deficiency in a healthy group of mothers and newborn infants. Clin Pediatr (Phila) 2007; 46:42-44. This article identifies Vitamin D deficiency in apparently healthy pregnant women and the risk to their newborn.
6. Park W, Paust H, Kaufmann HJ, Offermann G. Osteomalacia of the mother: rickets of the newborn. Eur J Pediatr 1987; 146:292-293.
7. Javaid MK, Crozier SR, Harvey NC, et al. Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet 2006; 367:36-43. This longitudinal study shows that Reduced concentration of 25(OH)-vitamin D in mothers during late pregnancy was associated with reduced whole-body and lumbar-spine bone-mineral content in children at age 9 years. The authors suggest that vitamin D supplementation of pregnant women, especially during winter months, could lead to longlasting reductions in the risk of osteoporotic fracture in their children.
8. Gregory J, Lowe S. National diet and nutrition survey: young children aged 4 to 18 years. London: Stationery Office; 2000. p. 796.
9. Bawa S. The role of the consumption of beverages in the obesity epidemic. J R Soc Health 2005; 125:124-128.
10. Kristensen M, Henriksen M, Molgaard C, et al. Short-term effects on bone turnover of replacing milk with cola beverages: a 10-day interventional study in young men. Osteoporos Int 2005; 16:1803-1808.
11. Benda CE, Bronner F, Harris RS, Maletskos CJ. Studies in calcium metabolism, effect of food phytates on calcium 45 uptake in boys on a moderate calcium breakfast. J Nutr 1956; 59:393-406.
12. Zhang ZB, Kornegay ET, Veit HP, et al. Comparison of phytase from genetically engineered Aspergillus and canola in weanling pig diets. J Anim Sci 2000; 78:2868-2878.
13. Ladizesky M, Holick MF, Mautalen C, et al. Solar ultraviolet B radiation and photoproduction of vitamin D3 in central and southern areas of Argentina. J Bone Miner Res 1995; 10:545-549.
14. Pettifor JM, Lu Z, Holick MF, et al. The effect of season and latitude on in vitro vitamin D formation by sunlight in South Africa. S Afr Med J 1996; 86:1270-1272.
15. 3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67:373-378.
16. Brazerol WF, Specker BL, Tsang RC, et al. Serial ultraviolet B exposure and serum 25 hydroxyvitamin D response in young adult American blacks and whites: no racial differences. J Am Coll Nutr 1988; 7:111-118.
17. Specker BL, Edwards N, Tsang RC, et al. Sunshine exposure and serum 25-hydroxyvitamin D concentrations in exclusively breast-fed infants. J Pediatr 1985; 107:372-376.
18. Matsuoka LY, Wortsman J, Chen TC, Holick MF. Compensation for the interracial variance in the cutaneous synthesis of vitamin D. J Lab Clin Med 1995; 126:452-457.
19. Clemens TL, Adams JS, Henderson SL, et al. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982; 1:74-76.
20. Matsuoka LY, Ide L, Wortsman J, et al. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab 1987; 64:1165-1168.
21. Matsuoka LY, Wortsman J, Hanifan N, et al. Chronic sunscreen use decreases circulating concentrations of 25-hydroxyvitamin D: a preliminary study. Arch Dermatol 1988; 124:1802-1804.
22. Grover SR, Morley R. Vitamin D deficiency in veiled or dark-skinned pregnant women. Med J Aust 2001; 175:251-252.
23. Robinson PD, Cowell CT, Ambler GR, et al. The re-emerging burden of rickets: a decade of experience from Sydney. Arch Dis Child 2006; 91:564-568.
24. Lawson M, Thomas M. Vitamin D concentrations in Asian children aged 2 years living in England: population survey. BMJ 1999; 318:28.
25. Shaw NJ, Pal BJ. Vitamin D deficiency in UK Asian families: activating a new concern. Arch Dis Child 2002; 86:147-149.
26. Awumey EM, Mitra DA, Hollis BW, et al. Vitamin D metabolism is altered in Asian Indians in the southern United States: a clinical research center study. J Clin Endocrinol Metab 1998; 83:169-173.
27. Harada S, Roden GA. Control of osteoblast function and regulation of bone mass. Nature 2003; 423:349-355.
28. Sabbagh Y, Carpenter TO, Demay MB. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci U S A 2005; 102:9637-9642.
29. Fomon SJ, Haschke F, Ziegler EE, Nelson SE. Body composition of reference children from birth to age 10 years. Am J Clin Nutr 1982; 35:1169-1175.
30. Dickerson JWT. Changes in the composition of the human femur during growth. Biochem J 1962; 82:56-61.
31. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity and weight velocity and the stages of puberty. Arch Dis Child 1976; 51:170-179.
32. Yilmaz D, Onur E, Pinar ED, et al. Bone mineral density in girls and boys at different pubertal stages: relation with gonadal steroids, bone formation markers, and growth parameters. J Bone Miner Metab 2005; 23:476-482.
33. Whiting SJ, Vatanparast H, Bailey DA, et al. Factors that affect bone mineral accrual in the adolescent growth spurt. J Nutr 2004; 134:696S-700S.
34. Gilbert S. Developmental Biology. 6th ed. Sunderland, Massachusetts; 2000.
35. Pettifor JM, Pentopoulos M, Ross FP, et al. Is craniotabes a pathognomonic sign of rickets in 3-month-old infants? S Afr Med J 1984; 7:549-551.
36. De Jong A, Callahan C, Weiss J. Pseudotumor cerebri and nutritional rickets. Eur J Pediatr 1985; 143:219-220.
37. Hanafy MM, Hassanein ES, el Khateeb S. Benign intracranial hypertension in vitamin D deficiency rickets associated with malnutrition. J Trop Pediatr Afr Child Health 1967; 13:19-22.
38. Willis FR, Beattie T. Craniosynostosis in X-linked hypophosphataemic rickets. J Paediatr Child Health 1997; 33:78-79.
39. Bereket A, Casur Y, Firat P, Yordam N. Brown tumour as a complication of secondary hyperparathyroidism in severe long-lasting vitamin D deficiency rickets. Eur J Pediatr 2000; 159:931.
40. Nikiforuk G, Fraser D. The etiology of enamel hypoplasia: a unifying concept. J Pediatr 1981; 98:888-893.
41. Purvis RJ, Barrie WJM, Belton NR, et al. Enamel hypoplasia of the teeth associated with neonatal tetany: manifestation of maternal vitamin deficiency. Lancet 1973; 2:811-814.
42. Rugg-Gunn AJ, Al-Mohammadi SM, Butler TJ. Malnutrition and developmental defects of enamel in 2- to 6 -year-old Saudi boys. Caries Res 1998; 32:181-192.
43. Uysal S, Kalayci AG, Baysal K. Cardiac functions in children with vitamin D deficiency rickets. Pediatr Cardiol 1999; 20:283-286.
44. Abdullah M, Bigras JL, McCrindle BW. Dilated cardiomyopathy as a first sign of nutritional vitamin D deficiency rickets in infancy. Can J Cardiol 1999; 15:1304.
45. Alyaarubi S, Rodd C. Treatment of malabsorption vitamin D deficiency myopathy with intramuscular vitamin D. J Pediatr Endocrinol Metab 2005; 18:719-722.
46. Schott GD, Wills MR. Muscle weakness in osteomalacia. Lancet 1976; 1:626-629.
47. Balkan C, Ersoy B, Nese N. Myelofibrosis associated with severe vitamin D deficiency rickets. J Int Med Res 2005; 33:356-359.
48. Stephan JL, Galambrun C, Dutour A, Freycon F. Myelofibrosis: an unusual presentation of vitamin D-deficient rickets. Eur J Pediatr 2000; 159:544.
49. 3 and its photoisomers in human skin. Science 1982; 216:1001-1003.
50. Blunt JW, Tanaka Y, DeLuca HF. Biological activity of 25-hydroxycholecalciferol, a metabolite of vitamin D3. Proc Natl Acad Sci U S A 1968; 61:1503-1506.
51. 3 in human skin. J Biol Chem 1993; 268:14888-14892.
52. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004; 29:664-673.
53. Cheng JB, Levine MA, Russell DW, et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Nat Acad Sci U S A 2004; 101:7711-7715.
54. 3 synthesis in the kidney. Nature 1978; 276:287-289.
55. 3-1alpha-hydroxylase in the human kidney. J Am Soc Nephrol 1999; 10: 2465-2473.
56. 3-1-alpha-hydroxylase gene promoter. Proc Nat Acad Sci USA 1998; 95:1387-1391.
57. Kawashima H, Torikai S, Kurokawa K. Calcitonin selectively stimulates 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase in the proximal straight tubule of the rat kidney. Nature 1981; 291:327-329.
58. 3 catalyzed by human CYP24. Eur J Biochem 2000; 267:6158-6165.
59. 3-24-Hydroxylase. Subcellular location and properties? Biochemistry 1974; 13:1543-1548.
60. 3 levels. Bone 2005; 36:654-662.
61. 3 is regulated by parathyroid hormone in UMR106 osteoblastic cells. Endocrinology 1998; 139:3375-3381.
62. 3 dependency of vitamin D receptor-retinoid X receptorvitamin D-responsive element complex formation. Arch Biochem Biophys 1997; 34:75-80.
63. Jehan-Kimmel C, Darwish HM, DeLuca HF, et al. Binding of vitamin D receptor to vitamin D response elements induces DNA distortion [abstract]. J Bone Miner Res 1996; 11:S312.
64. Gamble MJ, Freedman LP. A coactivator code for transcription. Trends Biochem Sci 2002; 27:165-167.
65. Masuyama H, Brownfield CM, St-Arnaud R, MacDonald PN. Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. Mol Endocrinol 1997; 11:1507-1517.
66. 3. Arch Biochem Biophys 2000; 381:143-152.
67. Jimi E, Nakamura I, Amano H, et al. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 1996; 137:2187-2190.
68. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597-3602.
69. Fu GK, Portale AA, Miller WL. Complete structure of the human gene for the vitamin D 1-alpha-hydroxylase, P450cl-alpha. DNA Cell Biol 1997; 16:1499-1507.
70. St-Arnaud R, Messerlian S, Glorieux FH, et al. The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res 1997; 12:1552-1559.
71. Scriver CR. Vitamin D dependency. (Editorial) Pediatrics 1970; 45:361-363.
72. 3-1-alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. New Engl J Med 1998; 338:653-661.
73. Wang X, Zhang MY, Miller WL, Portale AA. Novel gene mutations in patients with 1alpha-hydroxylase deficiency that confer partial enzyme activity in vitro. J Clin Endocrinol Metab 2002; 87:2424-2430.
74. Szpirer J, Szpirer C, DeLuca HF, et al. The Sp1 transcription factor gene (SP1) and the 1,25-dihydroxyvitamin D(3) receptor gene (VDR) are colocalized on human chromosome arm 12q and rat chromosome 7. Genomics 1991; 11:168-173.
75. Feldman DT, Chen C, Hochberg Z, et al. Vitamin D resistant rickets with alopecia: cultured skin fibroblasts exhibit defective cytoplasmic receptors and unresponsiveness to 1,25(OH)2D3. J Clin Endocrinol Metab 1982; 55:1020-1022.
76. Hughes MR, Malloy PJ, O'Malley BW, et al. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 1988; 242:1702-1705.
77. Malloy PJ, Hochberg Z, Pike JW, Feldman D. Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D-dependent rickets, type II. J Clin Endocrinol Metab 1989; 68:263-269.
78. Rosen JF, Fleischman AR, DeLuca HF, et al. Rickets with alopecia: an inborn error of vitamin D metabolism. J Pediatr 1979; 94:729-735.
79. Eil C, Liberman UA, Rosen JF, Marx SJ. A cellular defect in hereditary vitamin-D-dependent rickets type II: defective nuclear uptake of 1,25-dihydroxyvitamin D in cultured skin fibroblasts. New Engl J Med 1981; 304: 1588-1591.
80. Liberman UA, Halabe A, O'Riordan JLH, et al. End-organ resistance to 1,25-dihydroxycholecalciferol. Lancet 1980; 1:504-507.
81. Fraher LJ, Karmali R, O'Riordan JLH, et al. Vitamin D-dependent rickets type II: extreme end organ resistance to 1,25-dihydroxy vitamin D(3) in a patient without alopecia. Eur J Pediatr 1986; 145:389-395.
82. Kudoh T, Kumagai T, Nakao T. Vitamin D dependent rickets: decreased sensitivity to 1,25-dihydroxyvitamin D. Eur J Pediatr 1981; 137:307-311.
83. Marx SJ, Bliziotes MM, Nanes M. Analysis of the relation between alopecia and resistance to 1,25-dihydroxyvitamin D. Clin Endocrinol 1986; 25:373-381.
84. Balsan S, Garabedian M, Ricour C, et al. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. J Clin Invest 1986; 77:1661-1667.
85. al-Aqeel A, Ozand P, Marx S, et al. The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII). Clin Endocrinol 1993; 39:229-237.
86. Takeda E, Yamamoto H, Taketani Y, et al. Inorganic phosphate homeostasis and the role of dietary phosphorus. J Cell Mol Med 2004; 8:191-200.
87. HYP Consortium. A gene (HYP) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995; 11:130-136.
88. Lipman ML, Panda D, Karaplis AC, et al. Cloning of human PEX cDNA. Expression, subcellular localization, and endopeptidase activity. J Biol Chem 1998; 273:13729-13737.
89. Beck L, Soumounou Y, Tenenhouse HS, et al. Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-Iinked hypophosphatemic mice. J Clin Invest 1997; 99:1200-1209.
90. Ruchon AF, Marcinkiewicz M, Boileau G, et al. Pex mRNA is localized in developing mouse osteoblasts and odontoblasts. J Histochem Cytochem 1998; 46:459-468.
91. Du L, Desbarats M, Ecarot B, et al. cDNA cloning of the murine Pex gene and evidence for expression in bone. Genomics 1996; 36:22-28.
92. Blydt-Hansen TDm, Tenenhouse HS, Goodyer P. PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Pediatr Nephrol 1999; 13:607-611.
93. Jain A, Fedarko NS, Fisher LW, et al. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab 2004; 89:4158-4161.
94. Liu S, Brown TA, Quarles LD, et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 2005; 16:1645-1653.
95. Fukumoto S, Yamashita T. FGF23 is a hormone-regulating phosphate metabolism: Unique biological characteristics of FGF23. Bone 2007; 40:1190-1195. A comprehensive review on the role of FGF-23 as a phosphatonin, describing the role of FGF23 in X-linked hypophosphataemic rickets, autosomal dominant hypophosphataemic rickets and tumour induced osteolysis.
96. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003; 285:E1-E9.
97. Econs MJ, McEnery PT, Lennon F, Speer MC. Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 1997; 100:2653-2657.
98. Sabbagh Y, Londowski JM, Kumar R, et al. Stable transfection of PHEX in hypophosphatemic (Hyp) osteoblasts using a viral vector partially corrects the mutant cell phenotype. Implications for gene therapy. J Am Soc Nephrol 2000; 11:413A.
99. Econs MJ, McEnery MT. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997; 82:674-681.
100. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38:1310-1315. Mutational analyses have shown that 2 families with autosomal recessive hypophosphataemic rickets (ARHR) have mutations affecting the DMP-1 gene. DMP-1 null mice have high levels of circulating FGF-23 with a hypophosphataemic rickets phenotype. Defective DMP-1 produced by the osteocyte may result in elevated FGF-23 and ARHR.
101. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006; 38:1248-1250. Mutation of the DMP-1 gene at 4p21 which encodes a noncollagenous bone matrix protein expressed in osteoblasts and osteocytes has been identified in subjects with autosomal recessive hypophosphataemic rickets. Two of these subjects have an elevated FGF23. Crucially, this may suggest that osteocyte/osteoblast DMP-1 may be an important upstream regulator of FGF23.
102. Ziegler EE, O'Donnell AM, Nelson SE, Fomon SJ. Body composition of the reference fetus. Growth 1976; 40:329-341.
103. Abrams SA, Schanler RJ, Garza C. Bone mineralization in former very low birth weight infants fed either human milk or commercial formula. J Pediatr 1988; 112:956-960.
104. Moyer-Mileur LJ, Brunstetter V, Chan GM, et al. Daily physical activity program increases bone mineralization and growth in preterm very low birth weight infants. Pediatrics 2000; 106:1088-1092.
105. Bishop N. Bone disease in preterm infants. Arch Dis Child 1989; 64:1403-1409.
106. Fewtrell MS, Cole TJ, Bishop NJ, Lucas A. Neonatal factors predicting childhood height in preterm infants: evidence for a persisting effect of early metabolic bone disease? J Pediatr 2000; 137:668-673.
107. Lucas A, Brooke OG, Morley R, et al. High plasmaalkaline phosphatase activity and growth in preterm neonates. Arch Dis Child 1989; 64:902-909.
108. Bishop NJ, King FJ, Lucas A. Increased bone mineral content of preterm infants fed with a nutrient enriched formula after discharge from hospital. Arch Dis Child 1993; 68:573-578.